Sun Pharma’s Ambitious Move: Organon Acquisition and Funding Strategies
Sun Pharmaceutical Industries, led by Dilip Shanghvi, is making headlines with its definitive agreement to acquire US-based Organon & Co for $11.75 billion in an all-cash deal. This major pharma M&A transaction is set to reshape global pharmaceutical rankings and expand Sun Pharma’s international footprint. To fund the acquisition, Sun Pharma is actively exploring a mix of financing options, including Eurobonds, bond swaps, and offshore bank loans, a strategy that reflects the evolving landscape of pharma M&A.
Innovative Financing: Eurobonds and Bond Swaps Under Consideration
According to banking sources, Sun Pharma plans to raise approximately $10 billion from external sources, supplementing the remainder with its robust internal accruals. One of the primary financing routes being evaluated is the issuance of Eurobonds through a European Organon entity. This option is attractive for its potential tax advantages, given that the Eurobond market is among the largest global debt markets, offering issuers the flexibility to raise capital in over 50 currencies. Eurobonds are typically issued in a different currency than the country of sale, making them a strategic tool in large-scale pharma M&A deals.
In parallel, Sun Pharma is considering bond swaps, whereby existing Organon bondholders would exchange their holdings for newly issued Sun Pharma bonds. This swap could enhance the rating of the bonds, leveraging Sun Pharma’s AAA credit rating from agencies like Crisil and Icra. Such a move would not only facilitate the acquisition but also potentially reduce borrowing costs, aligning with best practices in pharma M&A financing.
Supplementary Funding: Offshore Loans and Internal Resources
Discussions are ongoing for additional offshore bank loans, estimated between $3 billion and $4 billion, to further support the acquisition. As of December 2025, Sun Pharma reported a net cash position of $3.2 billion, according to HDFC Securities. The company plans to deploy $2 billion to $2.5 billion from these internal accruals to fund the equity portion of the transaction. Brokerage firm Prabhudas Lilladher expects the remainder—$9.25 billion to $9.75 billion—to be financed through debt, underscoring the scale and complexity often involved in significant pharma M&A activities.
Financial heavyweights such as Citigroup Global Markets Asia, JPMorgan Chase Bank, and MUFG Bank are acting as financing partners, providing Sun Pharma with global expertise and access to diverse funding channels. This multi-pronged approach to deal financing is characteristic of modern pharma M&A strategies, where flexibility and risk management are key considerations.
Strategic Impact: Sun Pharma’s Global Ambitions
The acquisition of Organon will propel Sun Pharma into the ranks of the top 25 global pharmaceutical companies, boosting its combined revenue to an estimated $12.4 billion. The deal is more than just financial engineering; it’s a strategic move to deepen Sun Pharma’s global reach, enhance its licensing engine, and drive long-term efficiencies. By integrating Organon’s presence across 140 markets, Sun Pharma aims to accelerate growth and create a more balanced international portfolio—a hallmark ambition in pharma M&A transactions.
Organon’s product portfolio has been growing at a steady 1-2 percent annually. Sun Pharma’s management sees significant upside by leveraging the combined platforms to improve patient access, cross-pollinate product lines, and launch new offerings that deliver tangible value to end-users. The company is also positioning the new entity as a partner of choice for in-licensing innovative products, further strengthening its competitive edge post-acquisition.
Operational Efficiencies and Synergy Realization
Kirti Ganorkar, Sun Pharma’s Managing Director, has highlighted the potential for up to $350 million in cost synergies over the next two to four years. These operational efficiencies are expected to support strong cash flows and facilitate faster debt reduction, a critical factor in sustaining growth following a major pharma M&A event.
The deal is expected to close by early 2027, pending regulatory approvals and consent from Organon stockholders. After completion, Sun Pharma will be well-positioned to capitalize on its expanded scale, optimized geographic mix, and enhanced licensing capabilities.
Conclusion: A New Era in Pharma M&A
Sun Pharma’s pursuit of Organon, with its innovative financing mix and strategic growth agenda, marks a significant milestone in global pharma M&A. By utilizing Eurobonds, bond swaps, and leveraging internal strengths, Sun Pharma is setting a blueprint for complex cross-border acquisitions in the pharmaceutical sector. As the transaction moves forward, the industry will be watching closely to see how these financing strategies and integration plans unfold, potentially shaping future pharma M&A trends.
This article is inspired by content from Original Source. It has been rephrased for originality. Images are credited to the original source.